FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206934023> ?p ?o ?g. }

• W4206934023 endingPage "i465" @default.
• W4206934023 startingPage "i464" @default.
• W4206934023 abstract "Abstract Background Early initiation of TNF-antagonist (aTNF) therapy for Crohn’s disease (CD) is associated with greater clinical and endoscopic improvement but trialing an immunomodulator (IM) first remains common in paediatrics. This study aimed to determine if early aTNF is superior to IM maintenance therapy in paediatric luminal CD. Methods Children 2–17 years old with newly diagnosed CD were enrolled prospectively at one of 12 sites of the Canadian Children IBD Network. Patients with luminal inflammatory disease receiving IM or aTNF-based first maintenance therapy, following induction with steroids, exclusive enteral nutrition (EEN), or aTNF, were included. Those with perianal disease as the sole indication for aTNF were excluded. The primary outcome was sustained steroid-free clinical remission, defined by the short Pediatric CD Activity Index, at 6, 12, and 18 months, while continuing initial maintenance. A secondary outcome was combined sustained steroid-free clinical and endoscopic remission by 18 months, defined as the absence of ulcers at follow-up colonoscopy when ulcers were present at baseline. Multivariable logistic regression modeled the propensity of receiving aTNF maintenance therapy and 1:1 Greedy matching, without replacement, was used to match each of the participants who received aTNF with a participant who received an IM. The primary outcome was analyzed in the whole cohort, and in the subgroup receiving steroids or EEN as induction, using a Chi-square test, as well as in the matched group with a McNemar’s test, generalized estimating equation (GEE), and with a mixed model to account for clustering by centre. Sensitivity analyses with inverse probability treatment weights using GEE were performed. Results Among children with CD enrolled in the inception cohort study between 01/2014 and 12/2018, 464 met inclusion criteria and received IM (n=284) or aTNF (n=180 of whom 88 received steroids or EEN induction) as first maintenance therapy (Table 1). 162 patients were included in the matched cohort. In every analysis, more of the aTNF group achieved sustained 18-month steroid-free clinical remission, despite more severe baseline disease (Figure 1). The result remained significant in sensitivity analyses (Table 2). In patients with ulcers at baseline, 57.1% of the aTNF group versus 4.6% of the IM group achieved sustained steroid-free clinical remission and endoscopic remission by 18 months (p&lt;0.001). Conclusion In this paediatric cohort, aTNF was superior to IM as first maintenance therapy. These results may help advocate for better access and funding for early aTNF therapy in paediatric CD." @default.
• W4206934023 created "2022-01-26" @default.
• W4206934023 creator A5006121400 @default.
• W4206934023 creator A5008230538 @default.
• W4206934023 creator A5009290511 @default.
• W4206934023 creator A5009557875 @default.
• W4206934023 creator A5012343529 @default.
• W4206934023 creator A5013202046 @default.
• W4206934023 creator A5019018783 @default.
• W4206934023 creator A5020538296 @default.
• W4206934023 creator A5028349320 @default.
• W4206934023 creator A5029465719 @default.
• W4206934023 creator A5033717234 @default.
• W4206934023 creator A5049087079 @default.
• W4206934023 creator A5053069538 @default.
• W4206934023 creator A5055955847 @default.
• W4206934023 creator A5058329093 @default.
• W4206934023 creator A5062198630 @default.
• W4206934023 creator A5067218858 @default.
• W4206934023 creator A5067402350 @default.
• W4206934023 creator A5074820235 @default.
• W4206934023 creator A5075148718 @default.
• W4206934023 creator A5077809403 @default.
• W4206934023 creator A5079452400 @default.
• W4206934023 creator A5083384050 @default.
• W4206934023 creator A5084655458 @default.
• W4206934023 creator A5089211999 @default.
• W4206934023 date "2022-01-01" @default.
• W4206934023 modified "2023-10-18" @default.
• W4206934023 title "P503 Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn’s disease: A multi-centre prospective cohort study" @default.
• W4206934023 doi "https://doi.org/10.1093/ecco-jcc/jjab232.630" @default.
• W4206934023 hasPublicationYear "2022" @default.
• W4206934023 type Work @default.
• W4206934023 citedByCount "0" @default.
• W4206934023 crossrefType "journal-article" @default.
• W4206934023 hasAuthorship W4206934023A5006121400 @default.
• W4206934023 hasAuthorship W4206934023A5008230538 @default.
• W4206934023 hasAuthorship W4206934023A5009290511 @default.
• W4206934023 hasAuthorship W4206934023A5009557875 @default.
• W4206934023 hasAuthorship W4206934023A5012343529 @default.
• W4206934023 hasAuthorship W4206934023A5013202046 @default.
• W4206934023 hasAuthorship W4206934023A5019018783 @default.
• W4206934023 hasAuthorship W4206934023A5020538296 @default.
• W4206934023 hasAuthorship W4206934023A5028349320 @default.
• W4206934023 hasAuthorship W4206934023A5029465719 @default.
• W4206934023 hasAuthorship W4206934023A5033717234 @default.
• W4206934023 hasAuthorship W4206934023A5049087079 @default.
• W4206934023 hasAuthorship W4206934023A5053069538 @default.
• W4206934023 hasAuthorship W4206934023A5055955847 @default.
• W4206934023 hasAuthorship W4206934023A5058329093 @default.
• W4206934023 hasAuthorship W4206934023A5062198630 @default.
• W4206934023 hasAuthorship W4206934023A5067218858 @default.
• W4206934023 hasAuthorship W4206934023A5067402350 @default.
• W4206934023 hasAuthorship W4206934023A5074820235 @default.
• W4206934023 hasAuthorship W4206934023A5075148718 @default.
• W4206934023 hasAuthorship W4206934023A5077809403 @default.
• W4206934023 hasAuthorship W4206934023A5079452400 @default.
• W4206934023 hasAuthorship W4206934023A5083384050 @default.
• W4206934023 hasAuthorship W4206934023A5084655458 @default.
• W4206934023 hasAuthorship W4206934023A5089211999 @default.
• W4206934023 hasBestOaLocation W42069340231 @default.
• W4206934023 hasConcept C105795698 @default.
• W4206934023 hasConcept C126322002 @default.
• W4206934023 hasConcept C141071460 @default.
• W4206934023 hasConcept C1862650 @default.
• W4206934023 hasConcept C186282968 @default.
• W4206934023 hasConcept C201903717 @default.
• W4206934023 hasConcept C203092338 @default.
• W4206934023 hasConcept C27403532 @default.
• W4206934023 hasConcept C2776694085 @default.
• W4206934023 hasConcept C2778283404 @default.
• W4206934023 hasConcept C2779134260 @default.
• W4206934023 hasConcept C2779280984 @default.
• W4206934023 hasConcept C33923547 @default.
• W4206934023 hasConcept C53084192 @default.
• W4206934023 hasConcept C535046627 @default.
• W4206934023 hasConcept C71924100 @default.
• W4206934023 hasConcept C72563966 @default.
• W4206934023 hasConceptScore W4206934023C105795698 @default.
• W4206934023 hasConceptScore W4206934023C126322002 @default.
• W4206934023 hasConceptScore W4206934023C141071460 @default.
• W4206934023 hasConceptScore W4206934023C1862650 @default.
• W4206934023 hasConceptScore W4206934023C186282968 @default.
• W4206934023 hasConceptScore W4206934023C201903717 @default.
• W4206934023 hasConceptScore W4206934023C203092338 @default.
• W4206934023 hasConceptScore W4206934023C27403532 @default.
• W4206934023 hasConceptScore W4206934023C2776694085 @default.
• W4206934023 hasConceptScore W4206934023C2778283404 @default.
• W4206934023 hasConceptScore W4206934023C2779134260 @default.
• W4206934023 hasConceptScore W4206934023C2779280984 @default.
• W4206934023 hasConceptScore W4206934023C33923547 @default.
• W4206934023 hasConceptScore W4206934023C53084192 @default.
• W4206934023 hasConceptScore W4206934023C535046627 @default.
• W4206934023 hasConceptScore W4206934023C71924100 @default.
• W4206934023 hasConceptScore W4206934023C72563966 @default.
• W4206934023 hasIssue "Supplement_1" @default.
• W4206934023 hasLocation W42069340231 @default.
• W4206934023 hasOpenAccess W4206934023 @default.

• next